ImmunoCellular Therapeutics, Ltd. (IMUC) on the move this afternoon on good earning?

1598

Shares of [finviz_code ticker=IMUC item=2 value=”ImmunoCellular Therapeutics, Ltd.”] (NYSE:[finviz_code ticker=IMUC item=1 value=”IMUC”]) are currently up by more than [finviz_code ticker=IMUC item=60 value=”42.39%”] from the open today and are trading at $[finviz_code ticker=IMUC item=65 value=”3.45″]. More than [finviz_code ticker=IMUC item=67 value=”1,504,724″] shares have exchanged hands compared to an average trading volume of [finviz_code ticker=IMUC item=63 value=”276.36K”]. At the current pps, the market cap stands at $[finviz_code ticker=IMUC item=6 value=”8.23M”]. The stock prices of [finviz_code ticker=IMUC item=2 value=”ImmunoCellular Therapeutics, Ltd.”] (NYSE:[finviz_code ticker=IMUC item=1 value=”IMUC”]) are currently trading at [finviz_code ticker=IMUC item=57 value=”-19.28%”] below its 52 week high and [finviz_code ticker=IMUC item=58 value=”5439.87%”] above its 52 week low.

[finviz_code ticker=IMUC item=2 value=”ImmunoCellular Therapeutics, Ltd.”] (NYSE:[finviz_code ticker=IMUC item=1 value=”IMUC”]) has been in the news for all the right reasons. Recently, [finviz_code ticker=IMUC item=2 value=”ImmunoCellular Therapeutics, Ltd.”] (NYSE:[finviz_code ticker=IMUC item=1 value=”IMUC”]) announced that that the Board of Directors has appointed Anthony Gringeri, PhD, as Chief Executive Officer and a member of the Board of Directors. Dr. Gringeri has served as ImmunoCellular’s Senior Vice President of Strategic Resources since August 2013, and has led the implementation of the Company’s clinical and regulatory strategy for the ICT-107 phase 3 registration trial in newly diagnosed glioblastoma, as well as the ICT-121 phase 1 trial in recurrent glioblastoma. The appointment of Dr. Gringeri follows the decision by Andrew Gengos to resign the position of Chief Executive Officer. Mr. Gengos will continue to play an active role with the Company as a member of the Board of Directors, leveraging his broad experience in corporate strategy, financing, and business development. John Yu, MD, ImmunoCellular’s founder, will also continue to provide support to Dr. Gringeri and the management team in his continuing role on the Board of Directors.

[finviz_code ticker=IMUC item=2 value=”ImmunoCellular Therapeutics, Ltd.”] (NYSE:[finviz_code ticker=IMUC item=1 value=”IMUC”]) is all set to announce its earnings on [finviz_code ticker=IMUC item=68 value=”Feb 23/a”]. As per Zack’s analyst ratings, [finviz_code ticker=IMUC item=2 value=”ImmunoCellular Therapeutics, Ltd.”] (NYSE:[finviz_code ticker=IMUC item=1 value=”IMUC”]) currently has an average brokerage rating of [quandl_code ticker=IMUC item=ZAR|RATING_MEAN value=”3″]. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:[finviz_code ticker=IMUC item=1 value=”IMUC”]) is $[quandl_code ticker=IMUC item=ZAR|TP_MEAN_EST value=””] with a high of $[quandl_code ticker=IMUC item=ZAR|TP_HIGH_EST value=””] and a low of $[quandl_code ticker=IMUC item=ZAR|TP_LOW_EST value=””].

Let’s take a look at the technical analysis.

[intr_chart ticker=IMUC src=”http://www.financialstrend.com/wp-content/uploads/2017/02/25714-IMUC1.png”]

[intr_bto ticker=IMUC content=”ICAgIFRoZSBCYXJjaGFydCBUZWNobmljYWwgT3BpbmlvbiByYXRpbmcgaXMgYSA3MiUgQnV5IHdpdGggYSBTdHJvbmdlc3Qgc2hvcnQgdGVybSBvdXRsb29rIG9uIG1haW50YWluaW5nIHRoZSBjdXJyZW50IGRpcmVjdGlvbi4gICAgIExvbmdlciB0ZXJtLCB0aGUgdHJlbmQgc3RyZW5ndGggaXMgU3Ryb25nLiAgIExvbmcgdGVybSBpbmRpY2F0b3JzIG1vc3RseSBhZ3JlZSB3aXRoIHRoZSB0cmVuZC4gICAgICAg”]

The The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oid prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). [ema_code ticker=IMUC color=red value=2.46|2.65].

The relative strength index (RSI) is a momentum osciallator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). [rsi_code ticker=IMUC color=red value=48.20]

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.